Pros
Benefits are ok. Pay is ok although stagnant internally. Some good people remaining for now.
Cons
Micromanagement from managers who understand little. Disingenuous management who speaks in manner completely inconsistent with actions. Punitive and toxic culture. Performance failing as talent had fled poor decisions over last 5 years or more. Fraudulent leadership (HR at the center) taking advantage of good people. Too many Merck and Amgen imports who think too highly of those companies and brought the toxic, political realities (not recognizing that Biogen RTP HAS BEEN far better). Adu situation. Low raises for internal talent, HR meddling, taking talent base for granted, importing Merck/Amgen/BigPharma personnel, managing messaging rather than reality, numerous meetings over minutia and abstract nonsense, and a culture of losing. Biogen RTP 2021.